{
    "clinical_study": {
        "@rank": "13118", 
        "acronym": "REACT2", 
        "arm_group": [
            {
                "arm_group_label": "Enhanced Treatment Algorithm", 
                "arm_group_type": "Active Comparator", 
                "description": "The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings.  Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms."
            }, 
            {
                "arm_group_label": "Conventional Step-care Algorithm", 
                "arm_group_type": "Other", 
                "description": "Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Index (HBI)."
            }
        ], 
        "brief_summary": {
            "textblock": "Assess if the implementation of an enhanced treatment algorithm will improve the management\n      Crohn's Disease compared to a conventional Step-care approach."
        }, 
        "brief_title": "Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "detailed_description": {
            "textblock": "Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract.\n      During disease exacerbations, pharmacological or surgical intervention is usually needed to\n      re-establish remission.  Ideally, strategies should be employed to maintain patients in\n      long-term remission while minimizing exposure to corticosteroids and reduce therapy-related\n      toxicity.\n\n      Nevertheless, in reality many patients with CD do not receive effective therapy and their\n      disease often remains active, leading to uncontrolled inflammation and complications from\n      either the underlying disease or corticosteroids."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented diagnosis of CD\n\n          -  Written informed consent must be obtained and documented.\n\n          -  Willing to utilize study supply of adalimumab provided in syringe format, if\n             indicated according to treatment algorithm.\n\n        Exclusion Criteria:\n\n          -  Any conditions (e.g., history of alcohol or substance abuse) which, in the opinion of\n             the investigator, may interfere with the patient's ability to comply with study\n             procedures.\n\n          -  Latex allergy or other conditions in which adalimumab syringes are contraindicated\n\n          -  Currently participating, or planning to participate in a study involving\n             investigational product within 12 months that may interfere with the patient's\n             ability to comply with study procedures.\n\n          -  Previously failed all classes of tumor necrosis factor (TNF) antagonists for the\n             treatment of CD.\n\n          -  Diagnosis of short bowel syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698307", 
            "org_study_id": "RP1202"
        }, 
        "intervention": [
            {
                "arm_group_label": "Enhanced Treatment Algorithm", 
                "description": "The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings.  Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.", 
                "intervention_name": "Enhanced Treatment Algorithm", 
                "intervention_type": "Other", 
                "other_name": "Adalimumab"
            }, 
            {
                "arm_group_label": "Conventional Step-care Algorithm", 
                "description": "Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.", 
                "intervention_name": "Conventional Step-care Algorithm", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antimetabolites", 
                "Adalimumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Crohn's Disease", 
            "Deep Remission", 
            "Complications"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Shreveport", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "71101"
                    }, 
                    "name": "Louisana Research Center LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Asheville", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28801"
                    }, 
                    "name": "Asheville Gastroenterology Associates, PA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sudbury", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "P3C 5K6"
                    }, 
                    "name": "Sudbury Endoscopy Center"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease", 
        "other_outcome": {
            "description": "Disease progression is defined as the de novo development of strictures or fistula, the occurrence of an intra-abdominal abscess, or surgery for CD (resection, bypass, stricturoplasty).", 
            "measure": "Proportion of patients at one year who are in Deep Remission without disease progression", 
            "safety_issue": "No", 
            "time_frame": "twelve months"
        }, 
        "overall_official": {
            "affiliation": "Robarts Clinical Trials - Western University", 
            "last_name": "Brian G Feagan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United States: Food and Drug Administration", 
                "Germany: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CD-related complications include (1) CD-related surgeries and non-surgical CD events (such as disease flare, bowel obstruction, and bowel damage events (such as symptomatic bowel obstruction, fistula, abscess and CD related hospitalizations and 2) complications and hospitalizations related to CD medications or procedures.", 
            "measure": "Risk of CD-related complications at one-year, measured at the practice level", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "reference": [
            {
                "PMID": "23856361", 
                "citation": "Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Adalimumab Induces Deep Remission in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2013 Jul 12. doi:pii: S1542-3565(13)00924-5. 10.1016/j.cgh.2013.06.019. [Epub ahead of print]"
            }, 
            {
                "PMID": "18848553", 
                "citation": "Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008 Nov;135(5):1493-9. Epub 2008 Aug 3."
            }, 
            {
                "PMID": "20393175", 
                "citation": "Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492."
            }, 
            {
                "PMID": "18295023", 
                "citation": "D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenk\u00fchn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008 Feb 23;371(9613):660-7."
            }, 
            {
                "PMID": "16678077", 
                "citation": "Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May;4(5):621-30. Erratum in: Clin Gastroenterol Hepatol. 2006 Jul;4(7):931."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698307"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "CD-related complications include (1) CD-related surgeries and non-surgical CD events (such as disease flare, bowel obstruction, and bowel damage events (such as symptomatic bowel obstruction, fistula, abscess and CD related hospitalizations and 2) complications and hospitalizations related to CD medications or procedures.", 
            "measure": "Risk of CD-related complications at 6 months.", 
            "safety_issue": "No", 
            "time_frame": "six months"
        }, 
        "source": "University of Western Ontario, Canada", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Western Ontario, Canada", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}